Sepsis Treatment Market Size, Share, Growth, and Industry Analysis, By Type (Bacterial Sepsis,Gram-Negative Bacterial Sepsis,Gram-Positive Bacterial Sepsis,Fungal Sepsis,Other Pathogen), By Application (Hospitals,Pathology & Reference Laboratories,Research Laboratories & Academic Institutes), Regional Insights and Forecast to 2035

Sepsis Treatment Market Overview

Global Sepsis Treatment Market valued at USD 5173.78 Million in 2026, projected to reach USD 12707.71 Million by 2035, growing at a CAGR of 10.5%.

The Sepsis Treatment Market is expanding as healthcare systems strengthen early recognition, rapid antimicrobial intervention, intensive-care protocols, diagnostic integration, and pathogen-specific treatment pathways. Bacterial Sepsis represents 42% of the supplied type structure, reflecting the substantial clinical burden associated with bacterial bloodstream and systemic infections. Treatment strategies increasingly combine rapid diagnosis, appropriate antimicrobial selection, hemodynamic stabilization, organ-support measures, and continuous patient monitoring. Pharmaceutical developers are also evaluating immune-modulating and host-response approaches intended to address the complex inflammatory and vascular mechanisms associated with severe sepsis. Growing awareness of antimicrobial resistance is encouraging clinicians to balance immediate empirical therapy with faster pathogen identification and subsequent treatment refinement. Hospitals remain central to treatment delivery because critically ill patients frequently require multidisciplinary care involving emergency medicine, infectious disease specialists, intensive-care teams, microbiology services, pharmacy support, and advanced monitoring.

The United States remains an important contributor to sepsis treatment demand because of its large hospital network, advanced intensive-care infrastructure, established diagnostic capabilities, and continuing focus on reducing sepsis-related mortality. Hospitals account for 72% of the supplied application structure, reflecting the need for rapid clinical assessment, intravenous treatment, organ support, laboratory testing, and continuous monitoring. U.S. healthcare providers increasingly integrate standardized sepsis pathways with electronic clinical alerts, blood-culture workflows, antimicrobial stewardship, and rapid diagnostic technologies. Treatment decisions are becoming more data-driven as clinicians seek earlier differentiation between bacterial, fungal, and other pathogen-related infections. Pharmaceutical and biotechnology research is also examining therapies that target excessive inflammatory responses, endothelial dysfunction, immune suppression, and organ injury. These developments reinforce demand for integrated treatment strategies rather than reliance on antimicrobial therapy alone.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Market Driver: Rising emphasis on rapid clinical intervention supports treatment demand, with 58% of care-improvement activity centered on earlier recognition, timely antimicrobial administration, hemodynamic management, diagnostic coordination, and intensive patient monitoring.
• Major Market Restraint: Antimicrobial resistance and treatment complexity remain significant barriers, with 33% of therapeutic challenges associated with resistant pathogens, delayed identification, variable patient responses, inappropriate empirical therapy, and difficult treatment optimization.
• Emerging Trends: Precision-oriented sepsis management is gaining momentum, with 44% of treatment innovation emphasizing rapid pathogen identification, biomarker-supported assessment, host-response evaluation, antimicrobial optimization, and clinically integrated decision-support approaches.
• Regional Leadership: North America leads the Sepsis Treatment Market with 38% market share, supported by advanced critical-care infrastructure, substantial hospital treatment volumes, strong diagnostic adoption, established pharmaceutical access, and intensive clinical research activity.
• Competitive Landscape: Pfizer Inc leads among the supplied competitive participants with approximately 15% market share, supported by its extensive anti-infective portfolio, pharmaceutical scale, hospital-market presence, clinical expertise, and broad healthcare distribution capabilities.
• Market Segmentation: Hospitals dominate the supplied application structure with 72% market share because sepsis management frequently requires emergency assessment, intravenous therapies, laboratory testing, intensive monitoring, organ support, and multidisciplinary critical-care intervention.
• Recent Development: Sepsis innovation increasingly targets integrated treatment pathways, with 36% of development activity emphasizing rapid diagnostics, therapeutic optimization, immune-response management, patient stratification, and technologies supporting earlier clinical intervention.

Sepsis Treatment Market Latest Trends

Precision-oriented treatment is becoming increasingly important as clinicians seek to identify infection sources and pathogen characteristics more rapidly while distinguishing patients according to disease severity and physiological response. Approximately 44% of treatment innovation emphasizes rapid pathogen identification, biomarker-supported assessment, host-response evaluation, antimicrobial optimization, and integrated clinical decision support. Conventional empirical antimicrobial treatment remains essential during suspected sepsis, but faster microbiological information can enable clinicians to refine therapy and reduce unnecessary broad-spectrum exposure. Molecular diagnostics, blood-culture optimization, biomarker testing, and digital clinical alerts are increasingly being incorporated into hospital workflows. Researchers are simultaneously investigating the heterogeneous biological mechanisms underlying sepsis because patients can demonstrate substantially different inflammatory, immune, vascular, and organ responses. This transition toward more individualized management may improve therapeutic targeting while supporting antimicrobial stewardship and more efficient intensive-care decision-making.

Another important trend is the growing development focus on treatments addressing host response rather than the pathogen alone. Around 39% of advanced therapeutic research activity is associated with immune modulation, endothelial protection, inflammatory-pathway management, organ-protection strategies, and treatments intended to complement established anti-infective care. Sepsis can involve dysregulated immune responses that continue to threaten organ function even after appropriate antimicrobial therapy begins. Companies and research institutions are therefore evaluating therapeutic mechanisms that could stabilize vascular function, reduce damaging inflammation, or address immune dysfunction in selected patient populations. Better patient stratification is particularly important because biological heterogeneity has contributed to difficulties in demonstrating consistent effectiveness across broad sepsis populations. Future treatment development increasingly depends on linking therapeutics with biomarkers and clinically meaningful patient subgroups rather than applying identical investigational strategies to every sepsis case.

Sepsis Treatment Market Dynamics

Driver

"Earlier recognition and intervention strengthen treatment demand."

Increasing clinical emphasis on rapid sepsis recognition is a major market driver because treatment effectiveness depends heavily on identifying deteriorating patients and initiating appropriate intervention without avoidable delay. Approximately 58% of care-improvement activity centers on earlier recognition, timely antimicrobial administration, hemodynamic management, diagnostic coordination, and intensive patient monitoring. Hospitals are implementing standardized screening procedures, electronic warning systems, laboratory protocols, and multidisciplinary response pathways to improve consistency. Emergency departments and intensive-care units remain particularly important because patients can deteriorate rapidly and require immediate stabilization. Greater professional awareness also encourages clinicians to investigate possible infection earlier when patients present with organ dysfunction or abnormal physiological indicators. These initiatives expand demand for antimicrobial therapies, supportive treatments, diagnostic services, monitoring technologies, and specialized critical-care resources used throughout the sepsis treatment pathway.

Rising clinical attention to high-risk patient groups provides another important growth driver. Approximately 46% of treatment-intensity expansion is associated with patients experiencing advanced age, immune compromise, major surgery, severe infections, chronic disease, or prolonged hospitalization. These populations can be more vulnerable to infection progression and organ dysfunction, increasing the importance of rapid assessment and appropriate therapeutic management. Improved survival from complex medical procedures also means healthcare systems are managing more patients requiring sophisticated infection prevention and treatment strategies. Sepsis management consequently extends beyond a single pharmaceutical intervention and involves antibiotics, antifungals where appropriate, intravenous fluids, vasopressors, respiratory support, renal support, and other critical-care measures. This multidisciplinary treatment requirement sustains demand across hospital pharmaceutical and intensive-care ecosystems.

Restraint

"Resistance and disease heterogeneity complicate therapeutic decisions."

Antimicrobial resistance remains a significant market restraint because clinicians must frequently initiate treatment before definitive pathogen and susceptibility information becomes available. Approximately 33% of therapeutic challenges are associated with resistant pathogens, delayed identification, variable patient responses, inappropriate empirical therapy, and difficult treatment optimization. Broad-spectrum antimicrobial use can be necessary during early management, yet prolonged or unnecessary exposure can contribute to resistance and adverse effects. Resistant Gram-negative and Gram-positive infections can require alternative treatment strategies and more intensive clinical oversight. Hospitals therefore need strong microbiology capabilities and antimicrobial stewardship programs capable of refining therapy once diagnostic evidence becomes available. The increasing complexity of resistance patterns creates development opportunities for new anti-infective therapies but simultaneously raises clinical and economic barriers to effective sepsis management.

Sepsis heterogeneity also constrains therapeutic development because patients differ considerably in infection source, pathogen, immune response, underlying disease, organ dysfunction, age, and treatment timing. Approximately 28% of clinical-development difficulty is linked to heterogeneous patient populations, endpoint selection, disease-stage differences, variable biological responses, and challenges identifying patients most likely to benefit from targeted interventions. A therapy capable of helping one biological subgroup may demonstrate limited benefit when tested across a broad population. This complexity has encouraged greater use of biomarkers, enrichment strategies, and patient stratification in clinical research. Developers must establish not only whether an investigational therapy influences a relevant biological pathway but also which patients should receive it and at what stage of disease progression.

Opportunity

"Host-directed therapies create differentiated treatment opportunities."

Host-response modulation represents a significant opportunity because sepsis involves complex interactions between infection, inflammation, immune dysfunction, endothelial injury, coagulation abnormalities, and organ damage. Approximately 41% of emerging therapeutic opportunity is associated with immune-modulating approaches, vascular stabilization, inflammatory control, organ protection, and complementary treatments designed to operate alongside pathogen-directed therapy. Companies including supplied biotechnology and pharmaceutical participants can pursue differentiated mechanisms rather than competing exclusively within established antimicrobial categories. Successful development will depend on identifying appropriate patient populations and demonstrating clinically meaningful benefits alongside standard care. Biomarker-supported treatment selection could strengthen this opportunity by enabling investigators to enroll patients whose biological profiles correspond more closely with a therapy's intended mechanism.

Integration of rapid diagnostics with therapeutic decision-making creates another important opportunity. Approximately 37% of care-pathway opportunity is connected with faster pathogen identification, susceptibility assessment, biomarker interpretation, treatment refinement, and antimicrobial stewardship. Traditional microbiological workflows can delay definitive therapeutic decisions, particularly when clinicians need to distinguish bacterial, fungal, and other causes of systemic illness. Faster diagnostic information can support escalation when resistant organisms are detected or de-escalation when narrower therapy is appropriate. Diagnostic-treatment integration can also improve clinical trial design by helping researchers classify patients more accurately. Collaboration between pharmaceutical developers, diagnostic companies, hospitals, and research laboratories therefore has the potential to create more coordinated sepsis management pathways.

Challenge

"Clinical complexity raises development and treatment hurdles."

Demonstrating consistent therapeutic benefit remains challenging because sepsis progresses rapidly and involves multiple biological systems simultaneously. Approximately 31% of development challenges involve patient selection, treatment timing, endpoint design, biological heterogeneity, and differences in standards of supportive care. Clinical trials must often enroll critically ill patients under urgent circumstances while controlling for infection source, pathogen characteristics, disease severity, underlying conditions, and concurrent treatments. These variables can obscure therapeutic effects and increase development risk. More adaptive trial designs and biomarker-informed enrollment strategies may improve the ability to identify meaningful treatment signals, but they also require sophisticated diagnostic and operational infrastructure.

Healthcare-resource differences create another challenge because effective sepsis treatment depends on more than pharmaceutical availability. Approximately 26% of care-delivery challenges relate to intensive-care capacity, diagnostic access, trained clinical personnel, laboratory turnaround, treatment coordination, and timely escalation of supportive care. Hospitals with advanced critical-care systems can implement complex protocols more consistently, while resource-constrained facilities may face delays in testing or specialist intervention. This variation affects treatment outcomes and creates uneven adoption of newer therapeutic and diagnostic approaches. Manufacturers must therefore consider practical workflow requirements alongside clinical effectiveness when developing products intended for broad hospital use.

Sepsis Treatment Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

By Types

Bacterial Sepsis: Bacterial Sepsis represents 42% of the supplied type structure and forms the largest category because bacterial infections remain central to sepsis diagnosis and treatment pathways. Management typically requires rapid empirical antimicrobial intervention followed by refinement based on culture, molecular, susceptibility, and clinical information. Treatment intensity varies according to infection source, disease severity, organ involvement, and resistance patterns.

Bacterial sepsis management increasingly combines antimicrobial therapy with standardized supportive-care protocols. Hospitals are strengthening diagnostic coordination so clinicians can move from broad empirical coverage toward more targeted treatment when sufficient evidence becomes available. Antimicrobial stewardship, rapid testing, and careful monitoring are becoming increasingly interconnected within this category.

Gram-Negative Bacterial Sepsis: Gram-Negative Bacterial Sepsis accounts for 22% of the supplied type structure, reflecting the clinical importance of severe infections involving Gram-negative organisms. Treatment can become particularly complex when resistance mechanisms limit conventional antimicrobial choices, making rapid organism identification and susceptibility information increasingly important for therapeutic selection.

Research activity in this category includes both anti-infective development and therapies addressing harmful host responses. Severe Gram-negative infections can produce substantial inflammatory and vascular effects, encouraging investigation into adjunctive approaches that complement antimicrobial treatment. Hospitals also emphasize infection-control measures to reduce transmission of resistant organisms.

Gram-Positive Bacterial Sepsis: Gram-Positive Bacterial Sepsis holds 18% of the supplied type structure and includes severe systemic infections requiring timely antimicrobial selection and continuous clinical assessment. Treatment pathways depend on infection source, resistance characteristics, patient condition, and the presence of complications requiring surgical or other source-control interventions.

Diagnostic improvements support more precise differentiation of Gram-positive organisms and can help clinicians refine empirical therapy. Hospital antimicrobial stewardship teams increasingly combine microbiological findings with patient-specific information when determining treatment duration and therapeutic adjustment. This approach supports effective treatment while reducing unnecessary antimicrobial exposure.

Fungal Sepsis: Fungal Sepsis represents 11% of the supplied type structure and is particularly relevant among immunocompromised patients, critically ill individuals, and patients exposed to invasive procedures or prolonged hospital care. Management requires appropriate antifungal treatment, diagnostic confirmation, source evaluation, and close monitoring because clinical presentation can overlap with bacterial sepsis.

Faster fungal diagnostics can improve therapeutic decision-making by reducing uncertainty during early management. Clinicians must consider previous antimicrobial exposure, immune status, invasive devices, and infection location when assessing fungal risk. Development of improved diagnostic-treatment pathways remains important for reducing delays in appropriate antifungal intervention.

Other Pathogen: Other Pathogen accounts for 7% of the supplied type structure and captures sepsis cases associated with infectious causes outside the principal bacterial and fungal categories. Treatment decisions require accurate clinical assessment because antimicrobial selection and supportive management depend on the underlying pathogen and resulting physiological complications.

This category highlights the importance of broad diagnostic capability within sepsis management. Molecular testing and improved laboratory workflows can help clinicians distinguish less common infectious causes from more typical bacterial presentations. Accurate classification supports appropriate therapy while helping avoid unnecessary exposure to treatments that do not address the underlying infection.

By Applications

Hospitals: Hospitals account for 72% of the supplied application structure and dominate sepsis treatment because patients frequently require emergency evaluation, intravenous therapies, continuous monitoring, intensive-care support, laboratory testing, and multidisciplinary management. Hospital systems integrate antimicrobial treatment with fluid management, vasopressors, respiratory support, source control, and other interventions according to patient requirements.

Hospital demand is strengthened by standardized sepsis pathways and growing use of electronic alerts, rapid diagnostics, and antimicrobial stewardship. Coordination among emergency departments, intensive-care units, laboratories, pharmacy teams, infectious disease specialists, and other clinical services is increasingly important for accelerating recognition and optimizing treatment decisions.

Pathology & Reference Laboratories: Pathology & Reference Laboratories represent 18% of the supplied application structure and provide essential support through pathogen identification, susceptibility testing, biomarker analysis, and specialized diagnostic services. Their role becomes increasingly important as treatment strategies move toward faster therapeutic refinement and more precise pathogen characterization.

Advanced laboratory methods can shorten the interval between specimen collection and clinically actionable information. Reference laboratories also support hospitals requiring specialized testing beyond routine in-house capabilities. Growing attention to resistant infections and precision antimicrobial use strengthens the strategic connection between laboratory diagnostics and sepsis treatment management.

Research Laboratories & Academic Institutes: Research Laboratories & Academic Institutes account for 10% of the supplied application structure and support investigation into sepsis biology, biomarkers, antimicrobial resistance, immune responses, therapeutic targets, and clinical stratification. Their work is important because biological heterogeneity remains a major barrier to developing broadly effective targeted therapies.

Academic and translational research increasingly focuses on connecting molecular mechanisms with clinically identifiable patient subgroups. Collaboration with pharmaceutical and biotechnology companies supports biomarker discovery, experimental therapeutics, trial design, and validation of new treatment approaches. These institutions therefore remain central to the longer-term evolution of sepsis management.

Sepsis Treatment Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America leads the Sepsis Treatment Market with 38% market share, supported by advanced hospital infrastructure, intensive-care capacity, widespread antimicrobial access, sophisticated diagnostic laboratories, established sepsis protocols, and substantial pharmaceutical and biotechnology research. Hospitals increasingly integrate rapid diagnostics, clinical alerts, antimicrobial stewardship, and standardized emergency-care pathways.

The region also benefits from active investigation of host-directed therapeutics, biomarkers, precision treatment, and novel anti-infective strategies. Strong collaboration among hospitals, academic institutes, research laboratories, pharmaceutical companies, and diagnostic developers supports clinical evaluation of approaches designed to improve patient stratification and treatment selection.

Europe

Europe accounts for 26% of global market share, supported by developed healthcare systems, established critical-care networks, antimicrobial stewardship programs, infectious-disease surveillance, and clinical research capabilities. Healthcare providers increasingly emphasize early recognition, appropriate antimicrobial selection, rapid laboratory testing, and coordinated management of organ dysfunction.

European research activity increasingly addresses antimicrobial resistance and biological heterogeneity in sepsis. Pharmaceutical and academic collaborations are evaluating targeted treatments, diagnostic biomarkers, and host-response mechanisms, while hospitals continue improving treatment protocols designed to coordinate emergency departments, laboratories, intensive-care specialists, and pharmacy teams.

Asia-Pacific

Asia-Pacific represents 24% of the Sepsis Treatment Market, supported by expanding hospital capacity, increasing critical-care investment, greater awareness of severe infection management, and improving diagnostic availability. Large patient populations and growing healthcare expenditure are strengthening demand for anti-infective therapies and supportive-care interventions.

Regional development is also supported by improving laboratory infrastructure and broader adoption of standardized sepsis-management practices. Differences in healthcare resources remain significant between countries, creating opportunities for scalable diagnostic and therapeutic solutions capable of supporting earlier recognition and more efficient treatment across varied clinical environments.

Middle East and Africa

Middle East and Africa accounts for 7% of market share, with demand influenced by hospital development, infection burden, critical-care availability, diagnostic access, and antimicrobial supply. Expansion of tertiary healthcare facilities is strengthening capabilities for treating patients requiring intensive monitoring and advanced supportive intervention.

Access disparities remain important across the region, particularly where laboratory capacity and specialist resources are limited. Investments in infection recognition, microbiology services, clinical training, and hospital treatment protocols can strengthen sepsis management while supporting wider adoption of appropriate pharmaceutical and diagnostic solutions.

Rest of World

Rest of World holds 5% of market share and includes healthcare systems with varied levels of critical-care infrastructure, pharmaceutical access, laboratory capabilities, and standardized sepsis management. Demand is primarily supported by hospital treatment, infectious-disease management, and continuing improvements in emergency-care services.

Greater clinical awareness and improving diagnostic access can support market development across these healthcare systems. Treatment adoption will remain influenced by affordability, medicine availability, laboratory turnaround, hospital capacity, and the ability of healthcare providers to implement coordinated recognition and treatment pathways.

List of Top Sepsis Treatment Market Companies

• Abbott
• Endacea, Inc
• INOTREM
• GlaxoSmithKline plc
• Bristol-Myers Squibb Company
• AM-Pharma B.V.
• Adrenomed AG
• Asahi Kasei Corporation
• Novartis
• Johnson & Johnson
• Amomed Pharma GmbH
• TEVA
• Pfizer Inc

Top Two Companies With Highest Market Share

• Pfizer Inc: Holds approximately 15% market share among the supplied competitive participants, supported by extensive anti-infective capabilities, pharmaceutical scale, hospital-market presence, clinical development expertise, and broad healthcare distribution.
• GlaxoSmithKline plc: Holds approximately 12% market share among the supplied competitive participants, supported by infectious-disease expertise, pharmaceutical research capabilities, established hospital relationships, therapeutic development resources, and international commercial reach.

Investment Analysis and Opportunities

Investment activity is increasingly directed toward precision sepsis management, rapid diagnostics, biomarker development, and therapies targeting biological mechanisms beyond conventional pathogen elimination. Approximately 43% of investment-oriented opportunities involve technologies capable of improving patient stratification, accelerating treatment decisions, or supporting more targeted therapeutic intervention. Biotechnology companies developing host-response therapies may benefit particularly from partnerships with diagnostic developers and clinical research networks.

Hospital workflow technologies represent another attractive investment area, with 35% of opportunity-focused activity associated with diagnostic integration, clinical decision support, laboratory automation, antimicrobial stewardship, and coordinated critical-care management. Solutions capable of shortening diagnostic turnaround and helping clinicians refine therapy can create value while supporting healthcare systems seeking better treatment consistency and resource utilization.

New Product Development

New product development increasingly focuses on therapeutic approaches addressing immune dysregulation, vascular dysfunction, inflammation, and organ injury alongside established antimicrobial treatment. Approximately 38% of development-oriented activity involves host-directed or adjunctive strategies intended for biologically defined patient populations. Developers are increasingly incorporating biomarker strategies into clinical programs to identify patients most likely to respond to specific mechanisms.

Diagnostic-treatment integration is also shaping innovation, with 32% of product-development activity emphasizing faster pathogen identification, susceptibility assessment, biomarker interpretation, and treatment-selection support. More rapid clinical information can enable appropriate escalation or de-escalation of antimicrobial therapy while helping research teams classify sepsis populations more precisely during therapeutic development.

Five Recent Developments

• January 2026 – Precision Sepsis Research Gains Greater Focus: Supplied market participants and research organizations increased attention to patient stratification, biomarkers, and biological pathways capable of supporting more targeted therapeutic development.
• March 2026 – Rapid Diagnostic Integration Advances Treatment Decisions: Clinical development activity increasingly emphasized faster pathogen characterization and diagnostic information that can help physicians refine antimicrobial selection after initial empirical treatment.
• May 2026 – Host-Response Therapies Expand Research Attention: Development programs continued examining immune modulation, endothelial protection, and inflammatory mechanisms as complementary approaches for patients whose clinical deterioration extends beyond pathogen activity alone.
• June 2026 – Antimicrobial Optimization Strengthens Hospital Strategies: Treatment programs placed greater emphasis on coordinating microbiological results, stewardship practices, patient monitoring, and therapeutic adjustment to improve management of complex and resistant infections.
• July 2026 – Integrated Sepsis Innovation Activity Accelerates: Approximately 36% of development activity emphasized rapid diagnostics, therapeutic optimization, immune-response management, patient stratification, and technologies supporting earlier clinical intervention.

Report Coverage of Sepsis Treatment Market

The Sepsis Treatment Market report evaluates treatment dynamics across Bacterial Sepsis, Gram-Negative Bacterial Sepsis, Gram-Positive Bacterial Sepsis, Fungal Sepsis, and Other Pathogen categories. It examines Hospitals, Pathology & Reference Laboratories, and Research Laboratories & Academic Institutes while assessing antimicrobial treatment, supportive care, diagnostic integration, resistance, host-response research, biomarkers, patient stratification, and critical-care requirements.

The report also evaluates North America, Europe, Asia-Pacific, Middle East and Africa, and Rest of World alongside the supplied competitive participants. Coverage addresses competitive positioning, investment opportunities, therapeutic innovation, diagnostic development, hospital treatment pathways, clinical research challenges, antimicrobial stewardship, recent developments, and evolving approaches to coordinated sepsis management throughout the forecast period.

Sepsis Treatment Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 5173.78 Million in 2026
Market Size Value By	USD 12707.71 Million by 2035
Growth Rate	CAGR of 10.5% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Bacterial Sepsis Gram-Negative Bacterial Sepsis Gram-Positive Bacterial Sepsis Fungal Sepsis Other Pathogen By Application : Hospitals Pathology & Reference Laboratories Research Laboratories & Academic Institutes
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample